PDF (Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
8MB | |
PDF (Supplementary Files)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
Item Type: | Article |
---|---|
Title: | The BCL9-2 proto-oncogene governs estrogen receptor alpha expression in breast tumorigenesis |
Creators Name: | Zatula, N., Wiese, M., Bunzendahl, J., Birchmeier, W., Perske, C., Bleckmann, A. and Brembeck, F.H. |
Abstract: | The majority of human breast cancers express estrogen receptor {Alpha} (ER), which is important for therapy with anti-estrogens. Here we describe the role of BCL9-2, a proto-oncogene previously characterized as co-activator of Wnt/{beta}-catenin signaling, for mammary tumorigenesis in mice and human. ER positive human breast cancers showed overexpression of BCL9-2 and tamoxifen treated patients with high BCL9-2 demonstrated a better survival. BCL9-2 was upregulated during puberty and pregnancy in normal mammary epithelia, but downregulated in the involuted gland. BCL9-2 overexpression in vivo delayed the mammary involution and induced alveolar hyperplasia. Moreover, aged BCL9-2 transgenic mice developed ductal-like mammary tumors with high nuclear ER expression. We found, that primary cell cultures of BCL9-2 breast tumors responded to tamoxifen treatment. Moreover, BCL9-2 regulated the expression of ER and the proliferation of human breast cancer cells independently of {beta}-catenin. Finally, we describe a novel mechanism, how BCL9-2 regulates ER transcription by interaction with Sp1 through the proximal ESR1 gene promoter. In summary, BCL9-2 induces ER positive breast cancers in vivo, regulates ER expression by a novel {beta}-catenin independent mechanism in breast cancer cells, and might predict the therapy response to tamoxifen treatment. |
Keywords: | Mouse Model, Primary Cell Culture, Human Breast Cancer, Canonical Wnt Signaling, Estrogen Receptor Pathway, Pygo2, Sp1, Animals, Mice |
Source: | Oncotarget |
ISSN: | 1949-2553 |
Publisher: | Impact Journals |
Volume: | 5 |
Number: | 16 |
Page Range: | 6770-6787 |
Date: | 30 August 2014 |
Official Publication: | http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=2252&path[]=3720 |
PubMed: | View item in PubMed |
Repository Staff Only: item control page